Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant CAPOX + bevacizumab + pucotenlimab in high-risk resectable colorectal liver metastases
ChiCTR2400085958Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pucotenlimab, bevacizumab, capecitabine and oxaliplatin in colorectal cancer (CRC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: pathologic complete response. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
pucotenlimabbevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400085958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085958.